logo

Citius Pharmaceuticals, Inc. (CTXR)



Trade CTXR now with
  Date
  Headline
8/4/2020 8:20:08 AM Citius Says Submits Mino-Wrap Briefing Package To FDA For Pre-IND Consult
7/22/2020 10:34:33 AM Citius Forms Board For Development Of Proprietary Treatment For Acute Respiratory Disease Associated With COVID-19
7/14/2020 8:54:28 AM Myron Czuczman Joins Citius As Chief Medical Officer And EVP
7/13/2020 8:16:08 AM Citius Pharma Regains Compliance With Nasdaq Listing Requirements
6/26/2020 9:08:32 AM Citius Gets FDA Response On PIND Application For Its IMSCs To Treat ARDS In Patients With COVID-19; Stock Surges
6/2/2020 9:31:54 AM Citius Gets Positive FDA Feedback On Submitted Plan To Study Catheter Compatibility For Mino-Lok Therapy
5/26/2020 8:18:07 AM Citius Provides Free Access To Mino-Lok For Healthcare Providers
5/13/2020 8:22:44 AM Citius Pharma Says Data On NoveCite MSCs Will Be Presented This Week At ASGCT Annual Meeting
5/12/2020 8:08:05 AM Citius Pharma Highlights Exclusive Option To License Novel Stem-cell Therapy For ARDS Related To COVID-19 From Novellus
4/27/2020 9:31:52 AM Citius Announces Pre-IND Submission To FDA For Novel Stem Cell Therapy For ARDS In COVID-19
4/1/2020 8:11:17 AM Citius Signs Option With Novellus To License Novel Stem-Cell Therapy For ARDS Associated With COVID-19; Stock Surges
2/3/2020 8:10:29 AM Citius Pharma Says Regains Compliance With Nasdaq Listing Requirements
12/19/2019 8:04:50 AM Citius Announces Positive Outcome Of Analysis For Phase 3 Mino-Lok Pivotal Trial; DMC Recommends Continuation Of Trial
9/25/2019 7:06:01 AM Citius Announces Pricing Of $7.0 Mln Underwritten Offering Priced At-the-Market